Incyte Corporation

Incyte Corporation



Bookmark and Share Print This Page
Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.


Member in Photos


Member in the News


Nov

06

FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis

Incyte has first drug, Jakafi, approved by the FDA for patience with Myelofibrosis

Read More >

Apr

05

Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology Program

Incyte Corporation announced that it has earned a $15 million payment from Novartis based on the achievement of a predefined milestone in an ongoing Phase I dose

Read More >

Mar

15

Incyte Drug Nails Phase III Trial (again)

Incyte’s experimental blood cancer treatment, ruxolitinib, has delivered in another Phase III trial, this one led by co-developer Novartis in Europe.

Read More >

Apr

16

Incyte Honored as DelawareBio's Company of Year

Incyte, Inc. honored as DelawareBio's Company of the Year in recognition for Jakafi, the companies first FDA approved drug

Read More >